Carvedilol phosphate

Modify Date: 2024-01-05 16:22:11

Carvedilol phosphate structure	Common Name	Carvedilol phosphate
	CAS Number	610309-89-2	Molecular Weight	513.48
	Density	N/A	Boiling Point	655.2ºC at 760 mmHg
	Molecular Formula	C₂₄H₂₆N₂O_4.H₃PO_4.1/₂H₂O	Melting Point	N/A
	MSDS	N/A	Flash Point	350.1ºC

Use of Carvedilol phosphate

Carvedilol is a non-selective beta blocker/alpha-1 blocker with an IC50 of 3.8 μM for inhibition of LDL oxidation.IC50 Value: 3.8 μM ( inhibition of LDL oxidation)Target: beta Adrenergic ReceptorCarvedilol is a nonselective-blocking agent and is used in the treatment of hypertension and angina pectoris. As a third-generation β-adrenergic blocker (β-blocker), Carvedilol is able to reverse cardiac structural remodeling. Recentresults demonstrated that the effect caused by Carvedilol on cardiac remodeling is largely dependent on endogenous NO.

Name	1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol,phosphoric acid,hydrate
Synonym	More Synonyms

Description	Carvedilol is a non-selective beta blocker/alpha-1 blocker with an IC50 of 3.8 μM for inhibition of LDL oxidation.IC50 Value: 3.8 μM ( inhibition of LDL oxidation)Target: beta Adrenergic ReceptorCarvedilol is a nonselective-blocking agent and is used in the treatment of hypertension and angina pectoris. As a third-generation β-adrenergic blocker (β-blocker), Carvedilol is able to reverse cardiac structural remodeling. Recentresults demonstrated that the effect caused by Carvedilol on cardiac remodeling is largely dependent on endogenous NO.
Related Catalog	Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor Research Areas >> Cardiovascular Disease
References	[1]. Chen J, et al. The effects of carvedilol on cardiac structural remodeling: The role of endogenous nitric oxide in the activity of carvedilol. Mol Med Rep. 2013 Apr;7(4):1155-1158. [2]. Stafylas PC, et al. Carvedilol in hypertension treatment. Vasc Health Risk Manag. 2008;4(1):23-30. [3]. Othman AA, et al. Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. AAPS J. 2007 Jun 15;9(2):E208-18. [4]. Koshimizu TA, et al. Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-672.

Description

Related Catalog

Signaling Pathways >> GPCR/G Protein >> Adrenergic Receptor

Research Areas >> Cardiovascular Disease

References

[1]. Chen J, et al. The effects of carvedilol on cardiac structural remodeling: The role of endogenous nitric oxide in the activity of carvedilol. Mol Med Rep. 2013 Apr;7(4):1155-1158.

[2]. Stafylas PC, et al. Carvedilol in hypertension treatment. Vasc Health Risk Manag. 2008;4(1):23-30.

[3]. Othman AA, et al. Population pharmacokinetics of S(-)-carvedilol in healthy volunteers after administration of the immediate-release (IR) and the new controlled-release (CR) dosage forms of the racemate. AAPS J. 2007 Jun 15;9(2):E208-18.

[4]. Koshimizu TA, et al. Carvedilol selectively inhibits oscillatory intracellular calcium changes evoked by human alpha1D- and alpha1B-adrenergic receptors. Cardiovasc Res. 2004 Sep 1;63(4):662-672.

Boiling Point	655.2ºC at 760 mmHg
Molecular Formula	C₂₄H₂₆N₂O_4.H₃PO_4.1/₂H₂O
Molecular Weight	513.48
Flash Point	350.1ºC
PSA	172.54000
LogP	3.13600
Storage condition	-20℃

2-Propanol, 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-, phosphate, hydrate (2:2:1) (salt)

Carvedilol phosphate hydrate (JAN)

Carvedilol phosphate hemihydrate

Coreg CR (TN)

1-(9H-Carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}-2-propanol phosphate hydrate (2:2:1)

Carvedilol phosphate

Carvedilol (phosphate hemihydrate)

Carvedilol phosphate

Use of Carvedilol phosphate

Names

Carvedilol phosphate Biological Activity

Chemical & Physical Properties

Synonyms